APRINOIA offers patients with neurodegenerative diseases the hope of protecting their brain wealth and preserving their dignity through next-generation diagnostic tools and targeted therapeutics.
At APRINOIA, we bring precision medicine to neuroscience by identifying and targeting the protein aggregates of tau, α-synuclein, and other proteins that play a critical role in the pathogenesis of many neurodegenerative diseases, such as Alzheimer’s and Parkinson’s diseases.
We have several active diagnostic programs that aim to significantly improve the diagnosis of patients at early stages of disease and to potentially track the course of their disease in response to novel therapies. We have a robust pipeline comprised of small and large molecules that target proteins and related pathways underlying the causes of these disorders with the ultimate goal that such treatments will slow disease progression and preserve patients’ brain health before they’ve lost hope.
